Loading
A phase 1/2 trial of Cyclophosphamide, Fludarabine in ovarian cancer, run by Beijing Biotech, now recruiting.
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer is a phase 1/2 interventional study registered as NCT07589543 by Beijing Biotech, with 42 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-DUALNK, Cyclophosphamide, Fludarabine. Conditions listed: Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/